Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab Vial vs Prefilled Syringe Bioavailability Study in Healthy Subjects
NCT06268860Phase 1Completed
- Sponsor
- Amgen
- Start
- Feb 2024
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of rocatinlimab in atopic dermatitis (AD) (2 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Serum Concentration of Rocatinlimab, Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of Rocatinlimab and 1 more. Started Feb 2024; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06268860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268860.